Innovation

Targeting TMEM176B/A in the Cancer Immunity Cycle

TMEM176B/A blockade triggers systemic anti-tumoral immunity involving the intestinal compartment, secondary lymphoid organs and the tumor microenvironment. Inflammasome activation, CD4+ and exhausted CD8+ T cells are involved in these mechanisms.

Targeting TMEM176B/A in the Cancer Immunity Cycle

Scientific Leadership

With over ten years of exhaustive study upon mechanisms of cancer progression and immune system responses, our technology foundations lies within the scientific collaboration between two research laboratories at the Institut Pasteur of Montevideo.

Immunoregulatory and Inflammation Laboratory

Immunoregulatory and Inflammation Laboratory

 Chronic Lymphoid Leukemia Laboratory

Chronic Lymphoid Leukemia Laboratory

Research Publications

2024

Formulating a TMEM176B blocker in chitosan nanoparticles uncouples its paradoxical roles in innate and adaptive antitumoral immunity.

Sabina Victoria, Analía Castro, (…) Helena Pardo, Mercedes Segovia, M Hill.

International Journal of Biological Macromolecules

2022

The intracellular cation channel TMEM176B as a dual immunoregulator.

M Hill, S Russo, D Olivera, M Malcuori, G Galliussi, M Segovia.

Frontiers in Cell and Developmental Biology

2020

Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

M Segovia, S Russo, MR Girotti, GA Rabinovich, M Hill.

Clinical & Experimental Immunology

2019

Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation.

M Segovia, S Russo, M Jeldres, YD Mahmoud, V Perez, M Duhalde, … M Hill.

Cancer Cell